Zydis

Mar 17, 2020

Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

May 03, 2019

Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event

Apr 03, 2019

Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience

Mar 07, 2019

Catalent Invests Over $27 Million to Commercialize Zydis® Ultra, a Next Generation Oral Disintegrating Tablet

May 09, 2018

Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Mar 06, 2018

Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine

Mar 01, 2018

Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet

Feb 21, 2018

Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists

Jan 09, 2018

Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet

Nov 06, 2017

Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223